(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.52%) $78.89
(-1.18%) $2.17
(0.28%) $2 337.70
(0.26%) $27.69
(0.56%) $970.30
(-0.02%) $0.928
(-0.03%) $10.82
(-0.01%) $0.796
(0.00%) $91.35
0.00% HKD 0.880
Live Chart Being Loaded With Signals
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 331 000 |
Średni wolumen | 135 912 |
Kapitalizacja rynkowa | 652.52M |
EPS | HKD0 ( 2023-08-29 ) |
Następna data zysków | ( HKD0 ) 2024-05-28 |
Last Dividend | HKD0.00420 ( 2022-06-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -17.60 |
ATR14 | HKD0 (0.00%) |
Fusen Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fusen Pharmaceutical Finanse
Annual | 2023 |
Przychody: | HKD565.61M |
Zysk brutto: | HKD299.51M (52.95 %) |
EPS: | HKD-0.0500 |
FY | 2023 |
Przychody: | HKD565.61M |
Zysk brutto: | HKD299.51M (52.95 %) |
EPS: | HKD-0.0500 |
FY | 2022 |
Przychody: | HKD491.76M |
Zysk brutto: | HKD225.02M (45.76 %) |
EPS: | HKD-0.0458 |
FY | 2021 |
Przychody: | HKD385.66M |
Zysk brutto: | HKD211.13M (54.75 %) |
EPS: | HKD0.0210 |
Financial Reports:
No articles found.
Fusen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00620 | 2018-09-13 |
Last Dividend | HKD0.00420 | 2022-06-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.0436 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.1 | -- |
Div. Sustainability Score | 1.583 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.0742 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6806.HK | Ex Dividend Junior | 2023-06-26 | Annually | 0 | 0.00% | |
1905.HK | Ex Dividend Knight | 2023-10-20 | Semi-Annually | 0 | 0.00% | |
0934.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2886.HK | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
1501.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% | |
8095.HK | Ex Dividend Junior | 2023-10-17 | Sporadic | 0 | 0.00% | |
2005.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
1075.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0641 | 1.500 | -1.283 | -1.924 | [0 - 0.5] |
returnOnAssetsTTM | -0.0270 | 1.200 | -0.900 | -1.080 | [0 - 0.3] |
returnOnEquityTTM | -0.0612 | 1.500 | -1.791 | -2.69 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.853 | 0.800 | -0.735 | -0.588 | [1 - 3] |
quickRatioTTM | 0.329 | 0.800 | -2.77 | -2.22 | [0.8 - 2.5] |
cashRatioTTM | 0.0524 | 1.500 | -0.820 | -1.230 | [0.2 - 2] |
debtRatioTTM | 0.255 | -1.500 | 5.75 | -8.62 | [0 - 0.6] |
interestCoverageTTM | 6.34 | 1.000 | 8.76 | 8.76 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0619 | 2.00 | -0.0206 | -0.0412 | [0 - 30] |
freeCashFlowPerShareTTM | -0.118 | 2.00 | -0.0590 | -0.118 | [0 - 20] |
debtEquityRatioTTM | 0.609 | -1.500 | 7.57 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.530 | 1.000 | 4.51 | 4.51 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0379 | 1.000 | -1.241 | -1.241 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.135 | 1.000 | -1.862 | -1.862 | [0.2 - 2] |
assetTurnoverTTM | 0.421 | 0.800 | -0.527 | -0.422 | [0.5 - 2] |
Total Score | 1.583 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -16.77 | 1.000 | -1.795 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0612 | 2.50 | -1.151 | -2.69 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.118 | 2.00 | -0.0393 | -0.118 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0619 | 2.00 | -0.0206 | -0.0412 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0819 | 1.000 | -4.55 | 0 | [0.1 - 0.5] |
Total Score | -1.434 |
Fusen Pharmaceutical
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej